Clinical Effects of Sorafenib Combined with Transcatheter Arterial Chemoembolization on the Treatment of Advanced Primary Hepatocellular Carcinoma

Objective: Primary hepatocellular carcinoma(PHC) is one of the most common malignant tumors in the digestion system which is a serious threat to human health. At present, the preferred method of the advanced PHC is the transcatheter arterial chemoembolization(TACE) that could be better when combined with the anti-cancer drugs. With the function of inhibiting tumor cells' growth, sorafenib has been widely applied on the treatment of liver cancer. In view of the targeted qualification of the sorafenib, this study is written to discuss the curative effects of sorafenib combined with TACE on the treatment of advanced primary liver cancer, so that we could provide some references for clinical research. Methods: 96 cases with the advanced hepatocellular carcinoma who were treated in our hospital from October 2008 to June 2012 were selected and randomly divided into the control group and the observation group with 48 patients in each group. The patients in the control group were treated only by the TACE, while the patients in the observation group were treated by the sorafenib combined with TACE. Then the objective response rate(ORR), the clinical benefit rate(CBR), the survival rate of one year, the survival rate of more than two years and the alphafetoprotein(AFP) changes of patients were compared between two groups. Results: The ORR of the patients in the observation group was 52.1% and the CBR was 89.6% which were higher than those of the patients in the control group(33.3% and 47.9%) with statistical significant differences(P0.05). The survival rate of one year and more than two years were 89.6% and 72.9% which were higher than those of the patients in the control group(58.3% and 35.4%) with statistical significant differences(P0.05). The AFP levels were decreased of patients both in the two groups, but in which the observation group was superior to the control group(P0.05). Conclusion: It's worthy to widely promote the application of sorafenib combined with TACE on the clinical field for the efficacy is obvious and safe for patients with the advanced hepatocellular carcinoma.